Stockscreener 앱 받기
33.60
0.51%
0.17
시간 외 거래:
33.74
0.14
+0.42%
Gsk Plc Adr 주식(GSK)의 최신 뉴스
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - MSN
GSK Stock Declines 20% In 3 Months: Should You Buy, Sell Or Hold? - Barchart
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold? - Zacks Investment Research
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex - Benzinga
FDA Accepts GSK's Filing For Expanded Use Of Nucala In COPD - Barchart
GSK Expands Vaccine Collaboration With Zhifei in China - MSN
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US - MSN
The 10 Best US Companies to Invest in Now - Morningstar
GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo - Zacks Investment Research
10 Best Value Stocks to Buy for the Long Term - Morningstar
5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar
Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
The Best Defensive Stocks to Buy - Morningstar
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales - Yahoo Finance
What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar
21 Best Healthcare Companies to Invest In - Morningstar
Current share price is - GSK
D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily
GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News
What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register
GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register
What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise
Introducing Our Rant Against GSK Plc ADR - US Post News
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy - Zacks Investment Research
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily
Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily
JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily
GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
1.83%
1.48%
자본화:
|
볼륨(24시간):